An ultra-low-dose induction phase may help children with severe peanut or walnut allergies progress to conventional oral immunotherapy and tolerate milligram-level protein doses, according to an observational cohort study published in the journal Allergy Asthma Clin Immunol. The research tracked 21 pediatric patients older than age three between 2021 and 2024 who previously could not initiate treatment due to extreme reaction thresholds or histories of anaphylaxis.
Clinical Protocol for Severe Nut Allergies
Participants in the multicenter observational cohort study were divided into peanut allergy and walnut allergy groups after presenting with physician-diagnosed severe allergies. All patients had either a history of Grade 2 or higher allergic reactions, including anaphylaxis, or reacted to trace amounts of the allergen. To qualify, children required a positive skin prick test or elevated allergen-specific immunoglobulin E levels. Researchers determined starting treatment doses individually using serial five-fold dilutions of allergen extracts. Patients ingested the selected extract dose twice daily for one month. During monthly clinic visits, clinicians increased doses by adding drops and advancing to more concentrated extract dilutions if tolerated.
Patients transition to oral immunotherapy successfully
All peanut allergy participants and 90.9% of walnut allergy patients successfully transitioned to conventional oral immunotherapy. These patients tolerated milligram-level powder ingestion with a median transition time of 16 months for peanuts and 8 months for walnuts. Following treatment, most participants tolerated higher doses in allergen-drop challenges. Home-based drop maintenance yielded rare adverse reactions, calculated at 0.02% for peanuts and 0.09% for walnuts. These reactions were mostly mild to moderate, and no adrenaline was required at any stage of the home maintenance protocol.
Commercial Product Consumption and Anxiety Reduction
Beyond building physical tolerance to milligram-level protein doses, the treatment yielded functional dietary changes for a subset of participants. Researchers found that 30% of patients with peanut allergies and 27.3% of patients with walnut allergies could consume allergen-containing commercial products after completing the protocol. Investigators suggested that the benefits of ultra-low-dose induction extend beyond an increased reaction threshold by reducing daily anxiety related to accidental exposure. However, the study noted limitations, including the absence of a randomized comparison group and standardized allergen extracts, indicating that further research is required to confirm these findings.
Frequently Asked Questions
What specific diagnostic criteria were required for children to enter the trial?
Participants required physician-diagnosed severe peanut or walnut allergies, a positive skin prick test or elevated allergen-specific IgE levels, and either a history of Grade 2 or higher allergic reactions, including anaphylaxis, or reactions to trace amounts of the allergen.
What was the exact duration and dosing schedule of the induction phase?
Patients ingested an individually determined starting dose of allergen extract via serial five-fold dilutions twice daily for one month. In subsequent monthly clinic visits, the dose was increased by adjusting drop counts and moving to more concentrated extract dilutions.
What percentage of patients experienced adverse reactions during home maintenance?
Adverse reactions during home-based drop maintenance were rare, occurring in 0.02% of peanut cases and 0.09% of walnut cases, with reactions remaining mostly mild to moderate and requiring no adrenaline.
Worth a look